In response to adenosine 59-diphosphate, the P2Y 1 receptor (P2Y 1 R) facilitates platelet aggregation, and thus serves as an important antithrombotic drug target. Here we report the crystal structures of the human P2Y 1 R in complex with a nucleotide antagonist MRS2500 at 2.7 Å resolution, and with a non-nucleotide antagonist BPTU at 2.2 Å resolution. The structures reveal two distinct ligand-binding sites, providing atomic details of P2Y 1 R's unique ligand-binding modes. MRS2500 recognizes a binding site within the seven transmembrane bundle of P2Y 1 R, which is different in shape and location from the nucleotide binding site in the previously determined structure of P2Y 12 R, representative of another P2YR subfamily. BPTU binds to an allosteric pocket on the external receptor interface with the lipid bilayer, making it the first structurally characterized selective G-protein-coupled receptor (GPCR) ligand located entirely outside of the helical bundle. These high-resolution insights into P2Y 1 R should enable discovery of new orthosteric and allosteric antithrombotic drugs with reduced adverse effects.
. The blockade of either receptor significantly decreases ADP-induced platelet aggregation 4 . Although most of the available antithrombotic drugs act on P2Y 12 R, P2Y 1 R has been suggested as a new promising target, which may offer a safety advantage over P2Y 12 R inhibitors in terms of reduced bleeding liabilities 2 . Besides platelet aggregation, P2Y 1 R is also involved in many other physiological processes, such as vascular inflammation, and Ca 21 wave propagation and activation of extracellular signal-regulated kinase in astrocytes [5] [6] [7] . (19R,29S,49S,59S)-4-(2-Iodo-6-methylaminopurin-9-yl)-1-[(phosphato) methyl]-2(phosphato)bicycle[3.1.0]-hexane (MRS2500) is a potent P2Y 1 R antagonist that completely blocks ADP-induced platelet aggregation and effectively reduces arterial thrombosis with only a moderate prolongation of the bleeding time, which makes it an attractive candidate as an antithrombotic agent 8, 9 . Another ligand, 1-(2-(2-(tert-butyl) phenoxy)pyridin-3-yl)-3-(4-(trifluoromethoxy)phenyl)urea (BPTU), was recently discovered by Bristol-Myers Squibb as a novel P2Y 1 R antagonist that substantially reduces platelet aggregation with a minimal effect on bleeding, for the treatment of thrombosis 10 . To understand how these antithrombotic ligands recognize their purinoceptor target and to enable new drug discovery, we solved X-ray crystal structures of the human P2Y 1 R receptor bound to MRS2500 and BPTU (Extended Data Table 1 ), and performed a structure-guided mutagenesis study (Extended Data Table 2 ).
Overall architecture of P2Y 1 R
The P2Y 1 R structures share a canonical seven-transmembrane helical bundle architecture with other known GPCR structures (Fig. 1a, b and Extended Data Fig. 1 ). There are two disulfide bonds, connecting the N terminus to helix VII, and helix III to the second extracellular loop (ECL2), stabilizing the conformations of the ECLs. The ECL2 of P2Y 1 R exhibits a hairpin structure, which was previously observed in all the known peptide-bound GPCR structures, such as PAR1, NTSR1, chemokine and opioid receptors [11] [12] [13] [14] [15] . The conserved D[E]R 3.50 Y motif in class A GPCR family is replaced by an HR 3.50 Y motif in P2Y 1 R, making the crystal structure of P2Y 1 R the first GPCR structure with a basic histidine residue at position 3.49 (Ballesteros-Weinstein nomenclature 16 ) (Extended Data Fig. 2a ). Distinct from many other class A GPCRs, which contain a salt bridge between D [E] 3.49 and R 3.50 , H148 3.49 in P2Y 1 R repels R149 3.50 , resulting in a more extended side chain conformation of this residue. Consequently, R149
3.50 forms a hydrogen bond with the main chain of A327 7.56 at the intracellular tip of helix VII and stabilizes the C terminus in a different conformation compared to many other known class A GPCR structures. Like PAR1 and some other GPCRs, the P2Y 1 R structures lack helix VIII, and the C-terminal region beyond R338 appears disordered.
The two P2Y 1 R structures are similar (Ca root mean squared deviation (r.m.s.d.) within the entire receptor is 0.9 Å), except for subtle differences at the extracellular ends of helices I and II. Additionally, in the P2Y 1 R-MRS2500 structure, a salt bridge between R195 in ECL2 and MRS2500 shifts the b-hairpin tip of ECL2 by 2.6 Å towards the central axis of the helical bundle compared to the P2Y 1 R-BPTU structure (Extended Data Fig. 2b ). Compared with the recently solved structure of P2Y 12 R 17,18 belonging to a separate G i -coupled P2YR subfamily, P2Y 1 R is structurally distinct from either the agonist-bound or the antagonist-bound P2Y 12 R, with Ca r.m.s.d. within the helical bundle of 2.2 and 2.6 Å, respectively (Fig. 1c, d ). The extracellular tip of P2Y 1 R's helix VI has a position intermediate between the agonist and antagonistbound P2Y 12 R structures; whereas helix VII in P2Y 1 R is in a relatively similar conformation to the antagonist-bound P2Y 12 R structure. Unlike P2Y 12 R, P2Y 1 R has a highly conserved in class A GPCR residue P229 5.50 , which leads to a helical kink and displaces the extracellular end of helix V by over 4 Å compared to the P2Y 12 R structures. Another substantial difference between the helical bundles of the two purinergic receptors is that the extracellular end of helix III shifts away from the axis of the seven-transmembrane helical bundle by over 5 Å in P2Y 1 R compared to the P2Y 12 R structures. This apparent shift is probably due to the different conformations that the ECL2 adopts in P2Y 1 R and P2Y 12 R. The intracellular halves of the two P2Y receptors, however, are very similar with all helices overlaying each other relatively well.
Ligand-binding mode of P2Y 1 R-MRS2500
In the P2Y 1 R-MRS2500 structure, the ligand occupies a pocket defined by residues mainly from the N terminus, ECL2 and helices VI and VII ( Fig. 2 and Extended Data Fig. 3a) . The adenine ring of MRS2500 inserts into a binding crevice with R287
6.62 and L44 on either side, and its N 6 H and N 7 are coordinated by two hydrogen bonds with the N283 6.58 side chain, similar to adenine recognition in A 2A adenosine receptor (N 6.55 ) and P2Y 12 R (N 5.40 ) but at a different location. The 2-iodo group precisely fits into a small sub-pocket shaped by the P2Y 1 R's N terminus, and interacts with the main chain carbonyl of C42. This substituent has been shown to be critical for a high ligand-binding affinity to P2Y 1 R. Derivatives containing 2-bromo, chloro and fluoro substitutions exhibit much lower affinities than MRS2500 (ref. 8) . The N 6 -methyl group extends into another sub-pocket between helices VI and VII, forming hydrophobic interactions with A286
6.61 and N299 7.28 . The corresponding 6-amino analogue is 16-fold less potent, and any alkyl substitution larger than ethyl abolishes binding to P2Y 1 R 8 . The (N)-methanocarba ring makes a hydrophobic contact with the phenyl group of Y203 in ECL2. This is consistent with the observation that the Y203F mutation, but not Y203A, retains the ability to bind the nucleotide antagonist MRS2179 (ref. 19 ) (Extended Data Fig. 4 ). Both phosphate groups of nucleotide-like antagonists have been proven to be important for the high affinity interactions with P2Y 1 R 20 . In the P2Y 1 R-MRS2500 structure, each terminal oxygen of the two phosphates forms at least one contact with the receptor. The 39-phosphate makes hydrogen bonds with Y110 2.63 and Y303 7.32 and is engaged in two salt-bridge interactions with K46 at the N terminus and R195 in ECL2. The 59-phosphate forms a salt-bridge with R310
7.39 and makes hydrogen bonds with T205 in ECL2 and Y306 7.35 . Most of the above key residues of P2Y 1 R have not been previously tested for their involvement in either agonist or antagonist binding. Our mutagenesis studies have further confirmed the critical roles of these residues in ligand binding of P2Y 1 20, 21 . All of these residues are located much deeper than the MRS2500 binding site, but overlap well with the corresponding 2MeSADP binding site in the P2Y 12 R structure. This observation raises the possibility of a second potential nucleotide binding site in the P2Y 1 R receptor. Indeed, the P2Y 1 R-MRS2500 structure has a deeper cavity that partially overlaps with the position of the adenine ring of 2MeSADP bound to P2Y 12 R (Extended Data Fig. 6a ). In the current P2Y 1 R structure, however, the cavity is too small and the ECL2 extends deep into the ligand-binding pocket, blocking access to this potential binding site. Rearrangement of ECL2, as well as the helical bundle, would be required for a nucleotide to enter to this site. Nevertheless, it should be noted that the current data do not rule out the possibility that mutations of those residues may affect binding by changing the receptor conformation rather than by direct contact with a ligand.
The binding site of MRS2500 in P2Y 1 R locates much closer to the extracellular surface than the small-molecule ligand-binding sites in the other known GPCR structures (Extended Data Fig. 6b ). Comparing the antagonist binding sites in the three solved d group class A GPCR structures, the binding sites of AZD1283 in P2Y 12 R and vorapaxar in PAR1 are closer to helices IV and V than the MRS2500 binding site in P2Y 1 R (Extended Data Fig. 6c ). Although recognized by the same endogenous ligand ADP, P2Y 1 R and P2Y 12 R structures reveal very different features in binding their nucleotide-like ligands (Fig. 3) . The ligand-binding sites for MRS2500 in P2Y 1 R and 2MeSADP in P2Y 12 R are spatially distinct, with only a minor overlap of phosphate binding regions near the residues at position 7.35. The adenine groups of the two ligands are in different orientations. In the P2Y 1 R-MRS2500 structure, the adenine ring is adjacent to P2Y 1 R's helices VI and VII, whereas the adenine group of 2MeSADP reaches deep into the binding pocket to form hydrophobic interactions with helices III and IV in the P2Y 12 R structure.
A unique binding site for BPTU
The non-nucleotide ligand BPTU and other diarylurea P2Y 1 R antagonists have been recently introduced as novel antiplatelet agents 10, 22, 23 . Surprisingly, the P2Y 1 R-BPTU crystal structure reveals that instead of interacting within the seven-transmembrane helical bundle, BPTU binds to P2Y 1 R on the lipidic interface of the transmembrane domain. The relatively shallow ligand-binding pocket, formed by aromatic and hydrophobic residues of helices I, II and III and ECL1, accommodates BPTU predominantly through hydrophobic interactions ( 3.27 and Q127 3.28 . The hydrophobic nature of this sub-pocket is consistent with previous studies that have shown that the lipophilicity of this aryl group of the ligand is important for binding affinity and in vitro functional activity 22 . Similar to the A106 2.59 W mutant, the T103 2.56 W mutation abolished the binding affinity of BPTU to P2Y 1 R, but did not affect the binding of 2MeSADP and MRS2500 (Extended Data Table 2 ). The tert-butyl substituent of the phenoxy ring forms a hydrophobic contact with L102 2.55 in the P2Y 1 R-BPTU structure. SAR studies have shown that a lipophilic substitution of the phenoxy ring at either the ortho or meta position is preferred 10 , consistent with the fact that a para substitution may cause spatial clashes with receptor's helix III based on the P2Y 1 R-BPTU structure. At the other end of the ligand, the ureido phenyl ring forms two aromatic edge-to-face interactions with F62
1.43 and F66 1.47 . This aligns with the SAR requirement of aromatic monosubstitution of the urea N distal to the pyridine ring; replacing this aromatic ring with aliphatic substituents or inserting one or two methylene groups between a phenyl ring and the urea group decreased P2Y 1 R binding affinity dramatically 10 . The above consistency between the P2Y 1 R structure and the SAR studies has been validated also with docking simulations of several related, potent urea derivatives (Extended Data Fig. 7 ) that support the observed BPTU ligand-binding mode.
Previous efforts to reduce the lipophilicity of BPTU (HPLC logP 5 5.7) have shown that adding polar or basic amine groups to this ligand decreases binding affinity and antiplatelet activity; in fact, the binding affinity in this chemical series correlates directly with the HPLC logP value 24 . These data agree with our structure where the ligand BPTU binds in a highly hydrophobic environment. The structural features of the ligand-binding site and the high lipophilicity of BPTU suggest that this ligand most likely enters the ligand-binding pocket via the lipid bilayer, rather than through the highly charged nucleotide approach route that leads to the P2Y 1 R orthosteric site. The approach routes of hydrophobic GPCR ligands through the lipid bilayer have been proposed for several different receptors, such as rhodopsin, S1P1 and GPR40 [25] [26] [27] . However, the ligands bound to these receptors at least partially occupy the conventional GPCR ligand-binding pocket, and to our knowledge, BPTU is the first structurally characterized selective and high affinity GPCR ligand that binds entirely outside of the helical bundle of GPCRs. The location of this ligand-binding site indicates that BPTU acts as an allosteric modulator of P2Y 1 R. The allosteric regulation of P2Y 1 R by BPTU was studied by investigating its ability to influence the dissociation of [ 3 H]2MeSADP from the receptor. The data indicate that BPTU can substantially accelerate the dissociation of 2MeSADP, while the mutation A106
2.59 W abolishes the allosteric effect on the receptor by BPTU (Extended Data Fig. 8 ).
Insights into MRS2500 and BPTU inhibition mechanisms
Although MRS2500 and BPTU bind to distinct sites in P2Y 1 R, these two ligands stabilize the receptor in similar inactive conformations. In comparing the active state structures of several different GPCRs with their inactive structures, a relatively stable bundle of helices I to IV, and a more mobile module consisting of helices V, VI and VII have been observed, demonstrating that the rearrangements of helices V, VI and VII play important roles in the process of GPCR activation [28] [29] [30] . In P2Y 1 R, the antagonist MRS2500 potentially prevents such movements and stabilizes the receptor in an inactive state by interacting with helices VI and VII. In addition, it also bridges to the less mobile module through its 39-phosphate, a requirement for antagonism in this chemical series. However, in the BPTU-bound P2Y 1 R structure, the ligand makes no contacts with receptor's helices V, VI and VII, implying that BPTU inhibits receptor function in a different way. Besides the movements of helices V to VII, rotation and shift of helix III were also reported to be involved in the transformation from the inactive conformation to the active conformation of some GPCRs, although it is more subtle compared to the conformational changes of helices V to VII 17, [28] [29] [30] . The P2Y 1 R binding mode of BPTU suggests that this ligand most likely inhibits agonist-induced receptor activation by blocking relative movement of helices II and III, possibly a rotation of helix III. The above findings suggest that the movement of this less mobile module is equally critical for GPCR activation, in addition to the conformational changes of helices V to VII. Hindrance of the conformational plasticity of either domain may result in a severe loss of receptor function.
Conclusions
The P2Y 1 R structures reveal atomic details of two completely distinct ligand-binding sites having chemically and structurally contrasting characteristics: a hydrophilic and charged site for the nucleotide-like antagonist MRS2500 with numerous anchor points on different receptor domains and a shallow site on the outer, lipid-exposed surface for the non-nucleotide ligand BPTU stabilized by a single carbonyl polar interaction. A comparison between P2Y 1 R and P2Y 12 R shows that these representative structures of two different P2YR subfamilies interact with their nucleotide ligands in disparate binding modes, which deepen our understanding of the diversity of signal recognition mechanisms in GPCRs. The external, hydrophobic binding site of BPTU suggests the entry of this allosteric antagonist occurs through the lipid membrane, and opens new opportunities to broaden the scope of future GPCR ligand discovery to target novel allosteric sites outside of the canonical ligand-binding pocket. The P2Y 1 R structures also provide insights into the inhibition mechanisms of receptor activation by MRS2500 and BPTU through interactions with different domains of the receptor. 
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METHODS
Cloning and expression of engineered P2Y 1 R proteins. The wild-type (WT) human P2Y 1 R DNA was synthesized by Genewiz and then cloned into a modified pFastBac1 vector (Invitrogen) containing an expression cassette with an HA signal sequence followed by a Flag tag at the N terminus and a PreScission protease site followed by a 103 His tag at the C terminus. An engineered construct (construct 1) was generated by overlap extension PCR to insert M1-E54 of rubredoxin 31 between K247 and P253 in the intracellular loop 3 (ICL3) of P2Y 1 R. The P2Y 1 R gene was further modified by introducing the D320 7.49 N mutation to improve protein yield and stability. Another P2Y 1 R construct (construct 2) was made by adding A23-L128 of a thermostabilized BRIL (PDB ID: 1M6T) before the residue A8 of the receptor sequence in construct 1. High-titre recombinant baculovirus (.10 8 viral particles per ml) was obtained using the Bac-to-Bac Baculovirus Expression System (Invitrogen). Spodoptera frugiperda (Sf9) cells at cell density of 2 3 10 6 to 3 3 10 6 cells per ml were infected with virus at MOI (multiplicity of infection) of 5. Cells were collected by centrifugation at 48 h post-infection and stored at 280 uC until use. Purification of Sf9-expressed P2Y 1 R proteins for crystallization. Insect cell membranes were disrupted by thawing frozen cell pellets in a hypotonic buffer containing 10 mM HEPES, pH 7.5, 10 mM MgCl 2 , 20 mM KCl and EDTA-free complete protease inhibitor cocktail (Roche). Cell membranes were disrupted by repeated dounce homogenization. Extensive washing of the membranes was performed by centrifugation in the same hypotonic buffer (one more time), followed by a high osmotic buffer containing 1 M NaCl, 10 mM HEPES, pH 7.5, 10 mM MgCl 2 , 20 mM KCl (three times), thereby removing soluble and membrane associated proteins from the suspension of membranes, and then the hypotonic buffer (one more time) to remove the high concentration of NaCl. Purified membranes were resuspended in 10 mM HEPES, pH 7.5, 30% (v/v) glycerol, 10 mM MgCl 2 , 20 mM KCl and EDTA-free complete protease inhibitor cocktail, flash-frozen with liquid nitrogen, and stored at 280 uC until further use. Prior to solubilization, the purified membranes of construct 1-expressed materials were thawed on ice in the presence of 1 mM ATP (Sigma), 2 mg ml 21 iodoacetamide (Sigma) and EDTA-free protease inhibitor cocktail (Roche). After incubating at 4 uC for 1 h, the membranes were then solubilized in 50 mM HEPES, pH 7.5, 300 mM NaCl, 0.5% (w/v) n-dodecyl-b-D-maltopyranoside (DDM, Anatrace), 0.1% (w/v) cholesterol hemisuccinate (CHS) (Sigma), and 500 mM ATP for 3 h at 4 uC. The supernatant was isolated by centrifugation at 160,000g for 30 min, supplemented with 30 mM imidazole, pH 7.5, and incubated with TALON IMAC resin (Clontech) overnight at 4 uC. The resin was washed with ten column volumes of 25 mM HEPES, pH 7.5, 300 mM NaCl, 10% (v/v) glycerol, 40 mM imidazole, 0.05% (w/v) DDM, 0.01% (w/v) CHS and 1 mM ATP, followed by ten column volumes of 25 mM HEPES, pH 7.5, 300 mM NaCl, 10% (v/v) glycerol, 0.05% (w/v) DDM, 0.01% (w/v) CHS, 10 mM MgCl 2 , 5 mM ATP, and fifteen column volumes of 25 mM HEPES, pH 7.5, 300 mM NaCl, 10% (v/v) glycerol, 0.05% (w/v) DDM, 0.01% (w/v) CHS and 50 mM MRS2500. The protein was eluted by 25 mM HEPES, pH 7.5, 300 mM NaCl, 10% (v/v) glycerol, 300 mM imidazole, 0.05% (w/v) DDM, 0.01% (w/v) CHS and 100 mM MRS2500 in five column volumes. PD MiniTrap G-25 column (GE healthcare) was used to remove imidazole and increase the compound concentration to 1 mM. The protein was then treated overnight with His-tagged PreScission protease (home-made) and His-tagged PNGase F (home-made) to remove the C-terminal His-tag and de-glycosylate the receptor. PreScission protease, PNGaseF and the cleaved His tag were removed by Ni-NTA superflow resin (Qiagen) incubation at 4 uC for 1 h. The His-tag cleaved protein was collected in the Ni-NTA column flow through, and then concentrated to 40-50 mg ml 21 with a 100 kDa molecular weight cut-off Vivaspin concentrator (Sartorius Stedim Biotech). Receptor purity, monodispersity and concentration were estimated using SDS-PAGE and analytical size-exclusion chromatography (aSEC).
The P2Y 1 R-BPTU complex protein was purified following a protocol similar to the above procedure. The membranes of construct 2-expressed materials were incubated in 50 mM BPTU, 2 mg ml 21 iodoacetamide (Sigma), and EDTA-free protease inhibitor cocktail (Roche) at 4 uC for 1 h, and then solubilized in 50 mM HEPES, pH 7.5, 300 mM NaCl, 0.5% (w/v) DDM, 0.1% (w/v) CHS and 25 mM BPTU for 3 h at 4 uC. After overnight binding to the TALON IMAC resin, the resin was washed with thirty column volumes of 25 mM HEPES, pH 7.5, 300 mM NaCl, 10% (v/v) glycerol, 40 mM imidazole, 0.05% (w/v) DDM, 0.01% (w/v) CHS and 25 mM BPTU, and then eluted by five column volumes of 25 mM HEPES, pH 7.5, 300 mM NaCl, 10% (v/v) glycerol, 300 mM imidazole, 0.05% (w/v) DDM, 0.01% (w/v) CHS and 50 mM BPTU. Imidazole was removed using the PD MiniTrap G-25 column. The protein was further purified by the treatment with His-tagged PreScission protease and PNGase F. Lipidic cubic phase crystallization of P2Y 1 R-MRS2500 and P2Y 1 R-BPTU complexes. Purified protein samples of P2Y 1 R were reconstituted into lipidic cubic phase (LCP) by mixing with molten lipid in a mechanical syringe mixer 32 . The protein solution was mixed with monoolein/cholesterol (10:1 by mass) lipids at weight ratio of 1:1.5 (protein: lipid). After formation of a transparent lipidic cubic phase, the mixture was dispensed onto 96-well glass sandwich plates (Shanghai FAstal BioTech) in 40-50 nl drops and overlaid with 800 nl precipitant solution using a Mosquito LCP robot (TTP Labtech). Protein reconstitution in LCP and crystallization trials were performed at room temperature (19-22 uC) . Plates were incubated and imaged at 20 uC using an automated incubator/imager (RockImager, Formulatrix). The crystals of the P2Y 1 R-MRS2500 complex grew to their full size (70-150 mm) within two weeks in 20-30% PEG400 (v/v), 50-100 mM sodium citrate, 50 mM MRS2500, and 0.1 M HEPES, pH 7.0 or 0.1 M Tris-HCl, pH 8.0. The P2Y 1 R-BPTU complex was crystallized in 100-300 mM ammonium phosphate dibasic, 0-10% PEG2000 MME, 50 mM BPTU, and 0.1 M sodium citrate, pH 6.5, and the crystals reached their maximum size (100-130 mm) within two weeks. The P2Y 1 R crystals were collected directly from LCP using 50-100 mm micromounts (M2-L19-50/100, MiTeGen) and flash frozen in liquid nitrogen. Data collection and structure determination. X-ray diffraction data were collected at the SPring-8 beam line 41XU, Hyogo, Japan, using a Pilatus3 6M detector (X-ray wavelength 1.0000 Å). The crystals were exposed with a 10 mm mini-beam for 0.5 s and 0.5u oscillation per frame. XDS 33 was used for integrating and scaling data from 36 best-diffracting crystals of the P2Y 1 R-MRS2500 complex and 12 crystals of the P2Y 1 R-BPTU complex. Initial phase information of the P2Y 1 R-MRS2500 complex was obtained by molecular replacement (MR) with Phaser 34 using the receptor portion of PAR1 (PDB ID: 3VW7), converted to polyalanines, and rubredoxin structure (PDB ID: 1IRO) as search models. The correct MR solution contained two P2Y 1 R-rubredoxin molecules packed antiparallel in the asymmetric unit. Refinement was performed with REFMAC5 35 and BUSTER 36 followed by manual examination and rebuilding of the refined coordinates in the program COOT 37 using both j2F o j -jF c j and jF o j -jF c j maps. The final model includes 296 residues (38-247 and 253-338) of the 345 residues of P2Y 1 R and residues 1 to 54 of rubredoxin. The remaining N-and C-terminal residues are disordered and were not refined. The P2Y 1 R-BPTU complex structure was solved using P2Y 1 R in the P2Y 1 R-MRS2500 complex and rubredoxin as starting models and refined under the same procedure. The final model of the P2Y 1 R-BPTU complex contains 291 residues (38-156, 158-247 and 253-334) of P2Y 1 R and the 54 residues of rubredoxin. Without clear electronic density, the N-terminal fused BRIL was not traced. The crystal packing shows that there is no room to fit BRIL, indicating that it most likely degraded. Ligand-binding assays. Materials: 2MeSADP and MRS2500 were from Tocris (Minneapolis, USA). [ 3 H]2MeSADP at 4 uC for 30 min. Then the dissociation was initiated at 4 uC by mixing with 10 mM MRS2500 in the absence or presence of 10 mM BPTU (note that the dissociation at 25 uC was too fast to be measured). The reaction was terminated by harvesting with a 24-channnel Brandel cell harvester (Brandel, Gaithersburg, USA) and followed by washing twice with 5 ml cold Tris-HCl buffer containing 10 mM MgCl 2 . Radioactivity was measured using a scintillation counter (Tri-Carb 2810TR). Data were analysed using Prism 6 (GraphPad, San Diego, USA). Docking simulations of BPTU derivatives. The P2Y 1 R-BPTU structure was prepared using the Protein Preparation Wizard tool implemented in the Schrödinger suite, adding all the hydrogen atoms and the missing side chains of residues whose backbone coordinates were observed in the structure. The orientation of polar hydrogens was optimized, the protein protonation states were adjusted and the overall structure was minimized with harmonic restraints on the heavy atoms, to remove strain. Then, all the hetero groups and water molecules were deleted.
The SiteMap tool of the Schrödinger suite was used to identify potential binding sites in the structure. In addition to the canonical orthosteric binding site within RESEARCH ARTICLE the transmembrane bundle, a shallow pocket was identified on the external receptor interface with the lipid bilayer in correspondence of the BPTU crystallographic pose and was selected as the docking site. Molecular docking of several BPTU derivatives at the P2Y 1 R structure was performed by means of the Glide package from the Schrödinger suite. In particular, a Glide Grid was centred on the centroid of residues located within 5 Å from the previously identified cavity. The Glide Grid was built using an inner box (ligand diameter midpoint box) of 14 Å 3 14 Å 3 14 Å and an outer box (within which all the ligand atoms must be contained) that extended 20 Å in each direction from the inner one. Docking of ligands was performed in the rigid binding site using the SP (standard precision) procedure. The top scoring docking conformations accurately reproduced the binding mode observed for BPTU in the crystal and were in agreement with previous SAR findings for this class of compounds. Sample size. No statistical methods were used to predetermine sample size. 3.50 and A327 7.56 in P2Y 1 R is displayed as a blue dashed line. b, Comparison of the P2Y 1 R-MRS2500 complex and the P2Y 1 R-BPTU complex structures. The P2Y 1 R-MRS2500 structure is coloured in blue, and the P2Y 1 R-BPTU structure is orange. The ligands MRS2500 and BPTU are shown in stick representation with magenta and green carbons, respectively. The residues R195 in both structures are shown as sticks. The salt-bridge between MRS2500 and R195 in the P2Y 1 R-MRS2500 structure is displayed as a red dashed line. The red arrow indicates the shift at the b-hairpin tip of ECL2 towards the centre axis of the helical bundle in the P2Y 1 R-MRS2500 structure compared to the P2Y 1 R-BPTU structure. Table 2 . The affinity of MRS2500 at Construct 1 is 18.4 6 1.5 nM, which is significantly different from its affinity at the mutant Y303F (2880 6 854 nM) (P , 0.05, unpaired t-test). The affinity of BPTU for construct 1 is 161 6 47 nM, which is not significantly different from its affinity for Y303F (309 6 36 nM) (P . 0.05, unpaired t-test). e, f, Inhibition of [ ARTICLE RESEARCH
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